Perspective of a Neurosurgeon who treats Stroke

Adnan H. Siddiqui, MD, PhD
Professor & Vice-Chairman Department of Neurosurgery
Director Neurosurgical Stroke Service, Kaleida Health
Chief Medical Officer, Jacobs Institute

Presenting endorsed statement from
American Association of Neurological Surgeons (AANS)
Cerebrovascular Section of AANS & CNS
Society of Neurointerventional Surgery (SNIS)
Strokes Post TAVR  Multi-Factorial

Embolic material
  -Debris released during the procedure
Atrial fibrillation (new onset)
Hypo-perfusion
Hemorrhage
Preventable Strokes During TAVR

Embolic material released during TAVR

- Atheromatous Material
- Valve tissue
- Calcium
- Thrombus
- Foreign material
Clinical stroke Post TAVR under-recognized

Other Trans Aortic Arch Left Heart Procedures ??

- Most studies do not use routine MRI imaging post op
- Studies using discharge DETAILED exam by neurologists report much higher clinical stroke rates\(^2\) (Messé, et al., e.g.)

AHA/ASA consensus definition of stroke includes imaging evidence of a CNS infarction with or without acute neurological dysfunction\(^1\)

**30-day stroke rates in recent TAVI RCTs**

<table>
<thead>
<tr>
<th>Study</th>
<th>0%</th>
<th>5%</th>
<th>10%</th>
<th>15%</th>
<th>20%</th>
<th>25%</th>
<th>30%</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARTNER 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARTNER S3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARTNER S3 (2015)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADVANCE CV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADVANCE SXT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHOICE CV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHOICE SXT (2015)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gooley CV (2015)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gooley Lotus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REPRISE II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Rates of new neurological deficit with positive imaging evidence of brain ischemia**

<table>
<thead>
<tr>
<th>Study</th>
<th>0%</th>
<th>5%</th>
<th>10%</th>
<th>15%</th>
<th>20%</th>
<th>25%</th>
<th>30%</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLEAN-TAVI (Control arm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEFLECT III (Control arm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Messé (SAVR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Most Ischemic Injury in TAVR Unrecognized

- Major/disabling stroke
- Minor/non-disabling stroke
- Transient ischemic attack (TIA)
- Neurocognitive decline
- “Silent” cerebral infarcts

....but can have far-reaching effects
New cerebral lesions found in most patients following TAVR

Mounting evidence MRI lesions associated with delayed problems with cognition

- 68-100% of TAVI patients affected\(^1\)\(^{12}\)
- Most patients have multiple infarcts
- “Silent” infarcts associated with\(^13\)\(^{15}\)
  - 2-4-fold risk of future stroke
  - >3-fold risk of mortality
  - >2-fold risk of dementia
  - Cognitive decline
  - Dementia

New cerebral lesions found in most patients following TAVR

Mounting evidence MRI lesions associated with delayed problems with cognition

6. Lansky, et al., EHJ 2015; May 19
7. Bijuklic, et al., JACC; CVI 2015
8. Linke, et al., TCT 2014
13. Sacco et al., Stroke 2013
Embolic Protection Filters

Mounting evidence suggests they help
Debris captured in CAS filters 30-60%

Debris captured in TAVR filters 80-99%

Carotid filters captured debris in 57% of carotid stenting patients in ARCHeR (n=581 patients), including:

- Foam cells, smooth muscle cells, cholesterol, collagen/elastin, platelet/fibrin

Debris Captured in 99% of TAVR patients in SENTINEL (n=105 patients), including:

- Arterial wall
- Valve tissue
- Calcification
- Foreign material
- Myocardium
- Organizing and acute thrombus


CAUTION: Investigational device. Limited to investigational use by United States law.
Carotid vs TAVR

Which is which??

CAS

TAVR
TAVR and Stroke

- Subclinical stroke is a serious and under recognized problem
- What are the long-term neurocognitive sequelae to radiographic infarcts on MRI?
- Immediate recognition and restoring flow
Statement Endorsed by

- American Association of Neurological Surgeons (AANS)
- Cerebrovascular Section of AANS and Congress of Neurological Surgeons
- Society of Neurointerventional Surgery (SNIS)
American Association of Neurological Surgeons (AANS) and the Joint Cerebrovascular Section of AANS and Congress of Neurological Surgeons (CNS) and the Society of Neurolnterventional Surgery (SNIS) are committed to the prevention, management and recovery from acute ischemic stroke. We are uniquely aware of the inimitable relationship between the brain as an end-organ inherently impacted during therapies carried out in the heart or other antegrade vasculature.

Currently, the endovascular device-based therapeutic options available to treat cerebral infarcts are focused on large vessel occlusions, which are defined arbitrarily as occurring in cerebral arteries with a diameter of greater than 2.5mm. As evidenced by multiple international randomized prospective trials, even in practiced hands the successful extraction of debris in these cases, with a return to a pre-occlusion functional status remains approximately 50%. When treating the smaller strokes with an embolic origin, however, the current standard therapy is I.V. TPA, which has an even more modest success rate depending upon characterization of the debris and the location of the occlusion(s). It should be noted that post-interventional strokes are frequently ineligible for I.V.TPA given systemic use of heparin, fresh arterial puncture or other concurrent invasive procedures.
In instances, such as during transarterial valve replacement (TAVR), where the pathology of the stroke is a ‘showering effect’ of many small pieces of debris rather than the release of a single large piece of thrombus or calcium, the potential for success is diminished even further. In TAVR procedures, the spectrum of debris is also quite broad ranging from thrombus, arterial, ventricular and valvular tissue to myocardium as well as calcium nodules from the native valves and foreign material from the TAVR catheter. This spectrum of debris besides thrombus is most likely resistant to IV TPA and would otherwise require sophisticated mechanical intervention for removal of tissue. The clinical sequelae include vascular territory ischemia, and subsequent issues of physical, neurological and neurocognitive deficits.

The role of filter-based cerebral protection in the field of TAVR is supported by various studies that demonstrate the safe and effective entrapment and removal from the patient of both micro and macro debris caused by the delivery and deployment of the TAVR system and prosthesis in a heavily calcified aorta and aortic valve. By successfully removing debris before it reaches the brain, this protective technique serves to reduce the incidence of cerebral infarction without significant additional risk or procedure time.
We strongly support developing mechanisms to reduce incident risk of embolic shower to the brain during interventional cardiovascular procedures. We believe that such mechanisms carry the promise of improved neurologic and functional outcomes following these live saving procedures.
Would you do this?

CAS and TAVR Without Embolic Protection